CLINICAL TRIALS PROFILE FOR GABAPENTIN ENACARBIL
✉ Email this page to a colleague
All Clinical Trials for Gabapentin Enacarbil
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00311363 ↗ | Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome. | Completed | XenoPort, Inc. | Phase 3 | 2006-04-01 | The primary objective of this trial is to assess the maintenance of efficacy of gabapentin enacarbil (GEn, XP13512) taken once daily in the long-term treatment of patients suffering from Restless Legs Syndrome (RLS). |
| NCT00333359 ↗ | XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome. | Completed | XenoPort, Inc. | Phase 3 | 2006-06-01 | The primary objective of this trial is to assess the long-term safety and efficacy of XP13512 (Gabapentin Enacarbil) taken once daily for the treatment of patients suffering from Restless Legs Syndrome (RLS). |
| NCT00365352 ↗ | XP13512 vs. Placebo in Patients With Restless Legs Syndrome. | Completed | XenoPort, Inc. | Phase 3 | 2006-08-01 | The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS). |
| NCT00617461 ↗ | A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment | Completed | XenoPort, Inc. | Phase 2 | 2008-03-01 | The purpose of this study is evaluate the difference between two doses of gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn, on pain associated with post-herpetic neuralgia. |
| NCT00619476 ↗ | A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN) | Completed | XenoPort, Inc. | Phase 2 | 2008-02-01 | The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN). |
| NCT00643760 ↗ | A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN) | Completed | XenoPort, Inc. | Phase 2 | 2008-03-01 | The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with diabetic peripheral neuropathy(DPN) |
| NCT00748098 ↗ | Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance | Completed | XenoPort, Inc. | Phase 3 | 2008-10-01 | The purpose of this study is to assess the efficacy and safety of GSK1838262 extended release tablets in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Gabapentin Enacarbil
Condition Name
Clinical Trial Locations for Gabapentin Enacarbil
Trials by Country
Clinical Trial Progress for Gabapentin Enacarbil
Clinical Trial Phase
Clinical Trial Sponsors for Gabapentin Enacarbil
Sponsor Name
